https://www.selleckchem.com/pr....oducts/tecovirimat.h
In the originally treated group, over 40weeks, the decrease in PGMVC showed a significant (P0.001) quadratic component, indicating a plateauing at week 20. Findings reported here add new insights into the complex mechanisms of pseudo-atrophy and its relation to the compartmentalized inflammation occurring in the GM of MS patients. Ongoing and forthcoming clinical trials including MRI-derived GM volume loss as an outcome measure need to account for potentially significant GM volume changes as part of the initial treatment effect.
Like
Comment
Share
